Ann M. Fieuw - Publications

Efficacy and safety of the cystic fibrosis transmembrane conductance regulator inhibitor GLPG2737 for autosomal dominant polycystic kidney disease: phase 2a MANGROVE study.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: May 27, 2026

Interactive medical and safety monitoring in clinical trials with clinDataReview: a validated and open-source reporting tool.

Journal: Frontiers in medicine

Published: December 15, 2023

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.

Journal: JAMA

Published: May 09, 2023

Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS-5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip.

Journal: Clinical pharmacology in drug development

Published: April 19, 2021

Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis.

Journal: Contemporary clinical trials

Published: September 25, 2020

The autotaxin-lysophosphatidic acid pathway mediates mesenchymal cell recruitment and fibrotic contraction in lung transplant fibrosis.

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Published: July 26, 2020

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.

Journal: Clinical pharmacokinetics

Published: April 07, 2019

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

Journal: BMJ open respiratory research

Published: February 21, 2019

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.

Journal: Journal of clinical pharmacology

Published: November 29, 2018

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.

Journal: The Lancet. Respiratory medicine

Published: March 08, 2018